

Email: foi.tsdf@nhs.net
Our Ref: TSD10773

Dear Sir/Madam

Request for Information

We are writing to confirm that we have now completed our search for the information you requested.

A copy of the information is below:

I am conducting analysis on the use of biologic medicines in secondary care and kindly request your help.

I would be grateful if you could respond with the number of patients treated with specific medicines between the start of April 2026 and the end of June 2026, or the latest three-month period for which data is available. Please include data for all hospitals in your organization.

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	40
1.2 Depemokimab (Exdensur)	0
1.3 Dupilumab (Dupixent)	82
1.4 Mepolizumab (Nucala)	<5
1.5 Omalizumab (Xolair)	36
1.6 Reslizumab (Cinqaero)	0
1.7 Tezepelumab (Tezspire)	51

Q2. How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic Obstructive Pulmonary Disease (COPD)	Chronic rhinosinusitis with nasal polyps (CRwNP)
2.1 Benralizumab (Fasenra)			
2.2 Depemokimab (Exdensur)			
2.3 Dupilumab (Dupixent)			
2.4 Mepolizumab (Nucala)			
2.5 Omalizumab (Xolair)			
2.6 Reslizumab (Cinqaero)			
2.7 Tezepelumab (Tezspire)			

The Trust is unable to provide the requested breakdown for Q2, as the information is not held in an extractable/reportable format. Our Electronic Patient Record system does not allow us to produce a report showing the number of patients treated with the specified medicines by condition for the requested time period.

Q3. How many patients were treated for Atopic Dermatitis with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Name of medicine	Number of patients with Atopic Dermatitis	Number of patients with <u>Chronic Spontaneous Urticaria (CSU)</u>
3.1 Dupilumab (Dupixent)		

The Trust is unable to provide the requested breakdown for Q3, as the information is not held in an extractable/reportable format. Our Electronic Patient Record system does not allow us to produce a report showing the number of patients treated with the specified medicine for Atopic Dermatitis or Chronic Spontaneous Urticaria for the requested time period.

Q4. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Name of medicine	Respiratory departments	Dermatology departments	Other departments
4.1 Benralizumab (Fasenra)			
4.2 Depemokimab (Exdensur)			
4.3 Dupilumab (Dupixent)			
4.4 Mepolizumab (Nucala)			
4.5 Omalizumab (Xolair)			
4.6 Reslizumab (Cinqaero)			
4.7 Tezepelumab (Tezspire)			

The Trust is unable to provide the requested breakdown for Q4, as the information is not held in an extractable/reportable format. Our Electronic Patient Record system does not allow us to produce a report showing the number of patients treated with the specified medicines by department for the requested time period.

Low Numbers:

Where there are less than 5, we are unable to provide the exact information you require as this may enable the identification of our employees, members of the public or patients. This would constitute personal information and would be considered exempt under Section 40 of the Freedom of Information Act. Section 40 (FOI Act) provides an exemption to disclosure, where disclosure would contravene any of the Data Protection principles. This exemption is an absolute exemption that is not subject to the public interest test. Where the information relates to an individual who can be identified from that data, or from that data when added to other information, in the possession of, or likely to come into the possession of the data controller, this meets the definition of personal data as defined by the Data Protection Act.

The information supplied to you continues to be protected by the Copyright, Designs and Patents Act 1988. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting.

If you wish to discuss any of the above, please contact us, quoting the FOI reference number above.

If you are unhappy with the way in which we have handled your request, please contact the Data Protection and Freedom of Information Lead in the first instance. If you wish to make a formal complaint, you should write to our Complaints Manager at Torbay and South Devon NHS Foundation Trust, First Floor Bowyer Building, Torbay Hospital, Torquay TQ2 7AA or by email to tsdft.feedback@nhs.net

If you are not content with the outcome of your complaint or the internal review, you may apply directly to the Information Commissioner for a decision. Generally, the Information Commissioner will only make a decision once you have exhausted the complaints and/or internal review process provided by us. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF or through this link <https://ico.org.uk/global/contact-us/>

Yours sincerely,

Freedom of Information Team